As more and more people opt for coronavirus vaccination, we expect fewer cases of the illness. And that means less need for treatment, right? And bad news for treatment makers like Regeneron Pharmaceuticals (NASDAQ: REGN) ?
Not necessarily. In this Motley Fool Live video recorded on June 22, 2021 , healthcare and cannabis bureau editor and analyst Olivia Zitkus and Fool.com contributor Adria Cimino discuss why a big profit opportunity remains for Regeneron and other treatment makers.
For further details see:
Will an Increase in Vaccinations Hurt Regeneron's COVID Treatment Sales?